Singapore markets close in 3 hours 11 minutes
  • Straits Times Index

    3,070.74
    -5.70 (-0.19%)
     
  • Nikkei

    30,230.59
    +591.19 (+1.99%)
     
  • Hang Seng

    24,482.82
    -28.16 (-0.11%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • BTC-USD

    44,178.68
    +287.35 (+0.65%)
     
  • CMC Crypto 200

    1,103.23
    -5.69 (-0.51%)
     
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • Dow

    34,764.82
    +506.50 (+1.48%)
     
  • Nasdaq

    15,052.24
    +155.40 (+1.04%)
     
  • Gold

    1,752.30
    +2.50 (+0.14%)
     
  • Crude Oil

    73.43
    +0.13 (+0.18%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,532.60
    -6.74 (-0.44%)
     
  • Jakarta Composite Index

    6,142.73
    +0.01 (+0.00%)
     
  • PSE Index

    6,951.53
    +36.25 (+0.52%)
     

Is Inovio Pharmaceuticals Primed For a Comeback?

·4-min read
Is Inovio Pharmaceuticals Primed For a Comeback?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It seems like a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered a leader in the race to develop an effective coronavirus vaccine. Unsurprisingly, investors mostly gave up on Inovio, and its shares have lost more than half their value in the past 12 months. Inovio hasn't given up on its COVID-19 vaccine program, but the biotech can't conduct a phase 3 clinical trial for INO-4800 in the U.S. at the moment.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting